Study on novel coronavirus pneumonia (COVID-19) mechanism by Huashi Baidu Formula based on network pharmacology

• Main Authors: Yuan Liu, Jin-Bao Liu, Wei Peng
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2020-06-01
• Series: Journal of Hainan Medical University
• Subjects: huashi baidu formula; network pharmacology; chinese medicine; covid-19; sars-cov-2
• Online Access: http://www.hnykdxxb.com/PDF/202011/02.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To explore novel coronavirus pneumonia (COVID-19) by the method of network pharmacology. Methods: The compounds contained in the Huashi Baidu Formula were searched by TCMSP database, the active components and their action targets were screened, and the proteins were standardized by Uniprot database, and the drug-active ingredienttarget network was constructed by Cytoscape3.7.2 software. The targets related to COVID- 19 were screened by GeneCards database. STRING database and DAVID database were used to construct and analyze PPI network, GO analysis and KEGG enrichment analysis(P < 0.05). Results: The "drug-active ingredient-target" network of Huashi Baidu Formula consists of 176 components and 149targets, including AR, ESR1, PTGS2, PPARG, NOS2 and so on. 251 targets related to COVID-19. GO functional enrichment analysis showed that there were 179 biological processes, mainly related to inflammation, regulation of apoptosis and immune response, and 82 KEGG related signaling pathways were obtained, including HIF-1, TNF, small cell lung cancer, non-small cell lung cancer, tuberculosis, PI3K-Akt, NF- κ B, MAPK and so on. Conclusion: Huashi Baidu Formula may regulate the immune and inflammatory response of the body by acting on AR, ESR1, PTGS2, PPARG, NOS2 and other targets, which is the result of multi-component, multi-target and multi-channel interaction.